★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

Checking

Stock Profile

Zimmer Biomet Holdings, Inc. (ZBH) Moat Analysis

Zimmer Biomet Holdings, Inc.

ZBH · New York Stock Exchange

Market cap (USD)$19.5B
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of
Moat score
52/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Zimmer Biomet Holdings, Inc. is a Delaware orthopedic-device manufacturer whose ordinary shares trade primarily on the NYSE and secondarily on SIX; this is not an ADR structure. At July 30, 2026, exactly 190,737,689 common shares were outstanding. Q2 net sales were $2,177.0M: Knees contributed 38.1%, S.E.T. 26.9%, Hips 25.8%, and Technology & Data/Bone Cement/Surgical 9.2%. The defensible mechanisms are moderate procedure-specific familiarity and case-readiness support in knees and hips: entrenched clinical practice, product-specific training, consigned inventory, instruments, and field representatives create switching friction, but Stryker, J&J and Smith+Nephew maintain comparable systems and hospital standardization remains powerful. The service and workflow mechanisms are scored separately but conservatively to avoid treating the same incumbent footprint as two strong moats.

Primary segment

Knees

Market structure

Oligopoly

Market share

30.1% (reported)

HHI:

Coverage

4 segments · 5 tags

Updated 2026-08-23

Segments

Knees

Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation

Revenue

38.1%

Structure

Oligopoly

Pricing

weak

Share

30.1% (reported)

Peers

SYKJNJSNN

Hips

Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation

Revenue

25.8%

Structure

Oligopoly

Pricing

weak

Share

23.5% (reported)

Peers

SYKJNJSNN

S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)

Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices

Revenue

26.9%

Structure

Competitive

Pricing

weak

Share

Peers

SYKJNJSNN

Technology & Data, Bone Cement and Surgical

Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments

Revenue

9.2%

Structure

Oligopoly

Pricing

weak

Share

Peers

SYKJNJMDTISRG

Moat Claims

Knees

Knee reconstruction implants (primary, partial, revision) plus associated instruments and orthopedic robotics/navigation

Revenue share uses Q2 2026 product-category sales of $828.9M divided by $2,177.0M total. Product categories are economic sales groups rather than the company's geographic reportable segments, and product-level operating profit is not disclosed.

Oligopoly

Design In Qualification

Demand

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Knee systems require product-specific technique, instruments, training, and OR familiarity. The filing identifies entrenched clinical practice as an adoption barrier, supporting moderate qualification friction, but surgeons can retrain and large health systems can standardize vendors.

Design In Qualification moat: definition, examples, and stocks

Erosion risks

  • Hospital standardization reduces surgeon choice
  • New implant designs narrow differentiation
  • Shift of volume to price-sensitive ambulatory surgery centers

Leading indicators

  • Knee share trend vs SYK/JNJ/SNN
  • Pricing realization (net price/mix)
  • Adoption rates of new knee platforms and robotics-assisted procedures

Counterarguments

  • Surgeons can switch with retraining; competitors also run extensive education programs
  • Hospitals can force standardization via tenders and bundled purchasing

Service Field Network

Supply

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Consignment-heavy inventory and local clinical support improve case readiness and responsiveness. Replicating coverage is costly for a small entrant, but the other major orthopedic vendors operate comparable field and consignment models, limiting differentiation.

Service Field Network moat: definition, examples, and stocks

Erosion risks

  • Distributor/channel disruption
  • ERP/logistics execution issues
  • Hospital consolidation reduces the value of local density

Leading indicators

  • Backorder/fill-rate metrics
  • Rep productivity and churn
  • Customer complaint / service levels

Counterarguments

  • Large competitors have comparable field organizations and consignment models
  • Health systems may centralize inventory and reduce vendor footprint

Hips

Hip reconstruction implants (primary and revision) plus associated instruments and orthopedic robotics/navigation

Revenue share uses Q2 2026 product-category sales of $562.7M divided by $2,177.0M total. Product-level operating profit is not disclosed.

Oligopoly

Design In Qualification

Demand

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Hip systems are embedded in procedure-specific technique and instrument workflows, creating moderate retraining and qualification friction. This is not a hard lock-in: competitors offer comparable implant families and health systems can consolidate suppliers.

Design In Qualification moat: definition, examples, and stocks

Erosion risks

  • Commoditization of stems/cups
  • Purchaser-driven standardization and tendering

Leading indicators

  • Hip share trend vs SYK/JNJ/SNN
  • Revision mix and outcomes data publications

Counterarguments

  • Competitors offer comparable implant platforms and education programs

Service Field Network

Supply

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Local field coverage and consigned inventory support case readiness and responsiveness, but no category-specific service retention, response-time, or margin evidence establishes a strong advantage over incumbent peers.

Service Field Network moat: definition, examples, and stocks

Erosion risks

  • Distributor instability in certain regions
  • Execution issues that reduce service levels

Leading indicators

  • Order fill rates and backorders
  • Regional growth vs market

Counterarguments

  • Incumbent peers also operate large field organizations

S.E.T. (Sports Medicine, Extremities, Trauma, CMFT)

Sports medicine, extremities, trauma, biologics and CMFT orthopedic devices

Revenue share uses Q2 2026 product-category sales of $586.0M divided by $2,177.0M total. Paragon 28 contributed 2.8 percentage points to Q2 S.E.T. growth; acquisition contribution is not treated as moat evidence.

Competitive

Service Field Network

Supply

Strength

Strength 3 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

Field support and medical education aid case coverage across procedure types, but category breadth, acquisitions, and salesforce scale do not prove a durable advantage over equally capable orthopedic competitors.

Service Field Network moat: definition, examples, and stocks

Erosion risks

  • Distributor turnover in smaller markets
  • Margin pressure reduces ability to fund field headcount

Leading indicators

  • Salesforce productivity
  • Service-level metrics (fill rates, instrument availability)

Counterarguments

  • Peers also have sizable field teams; differentiation depends on execution

Technology & Data, Bone Cement and Surgical

Orthopedic surgical robotics and navigation, digital care pathways/analytics, bone cement, and surgical instruments

Revenue share uses Q2 2026 product-category sales of $199.4M divided by $2,177.0M total. Sales grew 21.1%, primarily from ROSA Robot and bone cement, but growth, an installed platform, and product breadth do not establish switching costs or proprietary lock-in without adoption, utilization, retention, or attach evidence.

Oligopoly

Evidence

sec_filing

may not be accepted quickly or at all ... because of ... entrenched patterns of clinical practice

Directly identifies established clinical workflows as a barrier to adoption of competing or new systems.

sec_filing

Consignment sales represented approximately 85 percent of our net sales in 2025.

Consignment plus local inventory/rep coverage increases service levels and raises the operational cost of switching vendors.

industry_report

Zimmer Biomet led... the knee... market with 30.1%... share...

Directly states 2023 worldwide knee implant share for Zimmer Biomet.

industry_report

Zimmer Biomet led... the... hip market with... 23.5%... share...

Directly states 2023 worldwide hip implant share for Zimmer Biomet.

sec_filing

We utilize a network of sales associates...

Supports the existence of a scalable service/sales footprint relevant to procedure-driven categories.

Risks & Indicators

Erosion risks

  • Hospital standardization reduces surgeon choice
  • New implant designs narrow differentiation
  • Shift of volume to price-sensitive ambulatory surgery centers
  • Distributor/channel disruption
  • ERP/logistics execution issues
  • Hospital consolidation reduces the value of local density

Leading indicators

  • Knee share trend vs SYK/JNJ/SNN
  • Pricing realization (net price/mix)
  • Adoption rates of new knee platforms and robotics-assisted procedures
  • Backorder/fill-rate metrics
  • Rep productivity and churn
  • Customer complaint / service levels

Keep the research going

Created 2025-12-23
Updated 2026-08-23

More Rankings & Systems

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.